THE MODERN BIO / FULL DIRECTORY
Every option.
Clearly sorted.
Browse popular prescription pathways and high-interest peptides across metabolic health, hormones, performance, sexual wellness, prevention, sleep and longevity. Status labels separate established uses from off-label and unapproved options.
Educational content only. Inclusion does not mean endorsement, availability or eligibility.Metabolic health & weight
Established metabolic prescriptions alongside emerging options that need a more careful evidence check.
GLP-1–based medications
Semaglutide, tirzepatide and related options for defined diabetes or chronic weight-management indications.
Open guide Mixed statusMetformin
A proven diabetes medication with an unresolved role as a general longevity drug.
Open guide FDA-approved usesOther weight-management medications
Phentermine/topiramate, naltrexone/bupropion and orlistat offer non-GLP-1 pathways for selected patients.
Open guide FDA-approved usesTesamorelin
An approved peptide for a narrow HIV-lipodystrophy indication—not general weight loss.
Open guide Not FDA-approvedRetatrutide
A triple-agonist peptide still in clinical development and not approved for consumer use.
Open guide Not FDA-approvedAOD-9604
A growth-hormone fragment marketed for fat loss without an approved indication or persuasive clinical outcome evidence.
Open guideHormones & fertility
Diagnosis-based options where symptoms, repeat testing, fertility goals and ongoing monitoring shape the decision.
Testosterone therapy
For properly confirmed testosterone deficiency with fertility and safety monitoring.
Open guide PrescriptionMenopause hormone therapy
Individualized systemic or local treatment based on symptoms, timing and personal risk.
Open guide Mixed statusClomiphene, enclomiphene & hCG
Male hormone and fertility pathways with different approvals, evidence and specialist uses.
Open guide PrescriptionThyroid medication
Laboratory-guided replacement for confirmed thyroid disease—not a general energy or weight-loss tool.
Open guide FDA-approved usesHuman growth hormone
Somatropin is legitimate replacement therapy for confirmed growth-hormone deficiency—not a routine anti-aging or bodybuilding drug.
Open guidePerformance, muscle & recovery
Popular recovery and growth-signaling compounds separated by human evidence, approved use and product-quality reality.
TB-500
A synthetic thymosin-beta-4 fragment promoted for injury recovery without an FDA-approved drug or established human protocol.
Open guide Not FDA-approvedCJC-1295
An unapproved growth-hormone signaling peptide with early human pharmacology but unproven performance outcomes.
Open guide Not FDA-approvedIpamorelin
An unapproved growth-hormone secretagogue commonly marketed for recovery, sleep and body composition.
Open guide Not FDA-approvedSermorelin
A growth-hormone-releasing peptide with historical approval and current compounded, off-label marketing context.
Open guide FDA-approved usesMecasermin / IGF-1
Approved for a rare pediatric IGF-1 deficiency—not a safe stand-in for bodybuilding products such as IGF-1 LR3.
Open guideSexual wellness
Options for blood flow, erectile function and selected desire concerns after cardiovascular and medication screening.
PDE5 inhibitors
Sildenafil, tadalafil and related prescription options for appropriate erectile-dysfunction care.
Open guide FDA-approved usesFemale desire medications
Flibanserin and bremelanotide have narrow HSDD indications and very different schedules, risks and eligibility rules.
Open guide FDA-approved usesBremelanotide (PT-141)
An approved peptide for a narrow premenopausal HSDD indication—not a universal libido treatment.
Open guide Mixed statusOxytocin
An established obstetric medication often marketed far beyond its approved clinical role.
Open guide Not FDA-approvedKisspeptin-10
A reproductive-signaling peptide that remains investigational.
Open guideSkin & hair
Evidence-based dermatology options separated from cosmetic marketing and unproven peptide claims.
Hair-loss medications
Topical minoxidil and prescription options such as finasteride, matched to the cause and pattern.
Open guide Mixed statusTretinoin & spironolactone
Prescription skincare options for selected acne, pigment and photoaging concerns.
Open guide Mixed statusGHK-Cu
A copper peptide used in cosmetic products with early, product-dependent human evidence.
Open guide Not FDA-approvedMelanotan II
An unapproved tanning peptide with meaningful product-quality and safety concerns.
Open guideHeart health & prevention
Mainstream prevention belongs in an optimization directory because controlling proven risk often matters more than adding another experimental compound.
Cholesterol-lowering medications
Statins, ezetimibe, PCSK9-directed therapies and other options matched to LDL/ApoB burden and overall risk.
Open guide FDA-approved usesBlood-pressure medications
Evidence-based drug classes selected from repeated readings, kidney function, conditions, side effects and pregnancy context.
Open guide FDA-approved usesGLP-1 cardiovascular-risk pathway
Selected incretin products carry cardiovascular indications for defined populations—not class-wide wellness claims.
Open guide Mixed statusLow-dose aspirin
Useful for selected secondary-prevention settings, but routine primary-prevention use can create avoidable bleeding risk.
Open guideSleep, focus & cognition
Diagnosis-first options for insomnia or excessive sleepiness, alongside popular neuropeptides whose marketing exceeds the evidence.
Prescription sleep medications
Orexin antagonists and other insomnia medicines may fit selected patients after CBT-I, apnea risk and next-day safety are reviewed.
Open guide Mixed statusModafinil / armodafinil
Wakefulness-promoting controlled medications for defined sleep disorders—not general-purpose nootropics.
Open guide Not FDA-approvedSemax
A neuroactive peptide marketed for focus and cognition without an FDA-approved U.S. drug product.
Open guide Not FDA-approvedSelank
An anxiolytic-style peptide with limited evidence and no FDA-approved U.S. indication.
Open guide Not FDA-approvedDSIP
A sleep-branded peptide with uncertain identity-to-outcome evidence and no approved product.
Open guideLongevity, immune & emerging
High-interest options where mechanisms, early research, approved uses and online marketing frequently get blurred together.
Low-dose naltrexone (LDN)
An off-label approach with condition-specific evidence and a critical opioid-interaction warning.
Open guide Off-labelRapamycin
An approved immunosuppressant with intriguing biology but no proven healthy-longevity indication.
Open guide Not FDA-approvedMOTS-c
A mitochondrial-derived peptide with intriguing biology but no established human treatment protocol or FDA-approved product.
Open guide Not FDA-approvedEpitalon
A longevity-marketed peptide supported mainly by preclinical and difficult-to-verify evidence.
Open guide Not FDA-approvedThymosin alpha-1
An immune-signaling peptide used in some countries, but not approved by FDA and limited by indication and product context.
Open guide Not FDA-approvedKPV
An anti-inflammatory peptide fragment with mostly preclinical evidence and no approved human use.
Open guide Not FDA-approvedLL-37
An antimicrobial host-defense peptide with experimental interest and meaningful inflammatory and product-quality uncertainty.
Open guideNEED A QUICKER START?